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ABSTRACT
Introduction Drivers of lower vaccine efficacy and impaired 
vaccine- specific immune responses in low- income versus 
high- income countries, and in rural compared with urban 
settings, are not fully elucidated. Repeated exposure to and 
immunomodulation by parasite infections may be important. 
We focus on Plasmodium falciparum malaria, aiming to 
determine whether there are reversible effects of malaria 
infection on vaccine responses.
Methods and analysis We have designed a randomised, 
double- blind, placebo- controlled, parallel group trial of 
intermittent preventive malaria treatment versus placebo, 
to determine effects on vaccine response outcomes among 
school- going adolescents (9 to 17 years) from malaria- 
endemic rural areas of Jinja district (Uganda). Vaccines 
to be studied comprise BCG vaccine on day ‘zero’; yellow 
fever, oral typhoid and human papilloma virus vaccines at 
week 4; and tetanus/diphtheria booster vaccine at week 
28. Participants in the intermittent preventive malaria 
treatment arm will receive dihydroartemisinin/piperaquine 
(DP) dosed by weight, 1 month apart, prior to the first 
immunisation, followed by monthly treatment thereafter. 
We expect to enrol 640 adolescents. Primary outcomes 
are BCG- specific interferon-γ ELISpot responses 8 weeks 
after BCG immunisation and for other vaccines, antibody 
responses to key vaccine antigens at 4 weeks after 
immunisation. In secondary analyses, we will determine 
effects of monthly DP treatment (versus placebo) on 
correlates of protective immunity, on vaccine response 
waning, on whether there are differential effects on 
priming versus boosting immunisations, and on malaria 
infection prevalence. We will also conduct exploratory 
immunology assays among subsets of participants to 
further characterise effects of the intervention on vaccine 
responses.
Strengths and limitations of this study
 ► This will be the first well- powered trial to evaluate 
the effect of repeated intermittent presumptive anti- 
malarial treatment on vaccine response outcomes 
in adolescents.
 ► Effects on both live- attenuated and inert vaccines 
will be studied.
 ► The use of an interventional research design will 
contribute strong evidence to determine whether 
malaria has causal and reversible effects on vaccine 
response outcomes, and our strong immunoepide-
miological design and nested immunological studies 
will make it possible to address specific hypotheses 
regarding pathways of effects.
 ► The use of vaccines most of which are part of 
Uganda’s national Expanded Programme on 
Immunisation, makes the findings from this study 
applicable and could inform the introduction of com-
bined school health programmes for malaria control 
and vaccine provision.
 ► With the high prevalence of malaria in the proposed 
study area, participants in the placebo arm may 
notice more frequent episodes of malaria and this 
could lead to individual self- unblinding and self- 
treatment, compromising the design of the study.
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Ethics and dissemination Ethics approval has been obtained from 
relevant Ugandan and UK ethics committees. Results will be shared with 
Uganda Ministry of Health, relevant district councils, community leaders 
and study participants. Further dissemination will be done through 
conference proceedings and publications.
Trial registration number Current Controlled Trials identifier: 
ISRCTN62041885.
INTRODUCTION
Population differences in vaccine- specific immune 
responses and efficacy have been documented. In trop-
ical low- income, rural settings, responses to both live1–6 
and non- live7 8 vaccines are often impaired, compared 
with urban and high- income country settings. Studies 
have also shown that responses to candidate vaccines 
(such as those to tuberculosis,9 malaria10 and Ebola11) 
are lower in Africa than in Europe or America. Drivers 
of these population differences in vaccine response are 
incompletely understood. While genetic differences may 
play a role, they cannot fully explain this phenomenon: 
for example, migrant and native English populations 
have comparable BCG vaccine efficacy.12 Previous expo-
sure to the pathogen targeted by the vaccine, or to related 
organisms, may mask the benefit of the vaccine;13 14 
however, this mechanism cannot explain observations for 
vaccines against rare organisms such as Ebola.11 The role 
of immunomodulating environmental factors has been 
discussed,2 but evidence is inconclusive. Parasites, partic-
ularly, have long been proposed as modulators of vaccine 
responses,15 16 but this has not been fully substantiated 
in well- powered trials aimed at evaluating reversibility of 
their effects in human populations.17
This study is one of three parallel trials whose designs 
and cross- cutting analyses are described separately in this 
journal (bmjopen-2020-040425, bmjopen-2020-040426 
and bmjopen-2020-040430). The focus of this POPulation 
differences in VACcine responses (POPVAC) B trial is on 
infection with malaria parasites. Malaria remains highly 
prevalent in Africa and Uganda is among the six coun-
tries with the highest prevalence of malaria parasites on 
the continent.18 A recent nationally representative survey 
estimated parasite prevalence (based on microscopy) of 
32% in children aged 8 to 10 years, with wide variability 
by region.19 Emerging insecticide and drug resistance 
threatens gains towards control.20 Interventions like inter-
mittent preventive treatment (IPT) are recommended 
by the WHO for use in preventing malaria in pregnant 
women, infants and young children living in areas of 
seasonal malaria transmission.20 In a recently concluded 
trial in Uganda, IPT in schoolchildren was shown to be 
beneficial in protecting individual children and reducing 
community transmission of malaria.21 22
Several studies have previously reported impaired 
meningococcal, tetanus and typhoid vaccine responses 
in children infected with malaria parasites.23–26 Another 
study showed that children receiving malaria chemopro-
phylaxis had better responses to meningococcal vaccine 
than children not receiving malaria chemoprophylaxis.27 
In a Ugandan study, malaria infection in mothers during 
pregnancy, and in their infants, was associated with 
reduced antibody responses to measles immunisation in 
infancy.28 We have previously observed that infant malaria 
infection is associated with reduction in BCG and tetanus 
vaccine- specific responses.29 On the other hand, malaria 
infection could improve responses to some vaccines and 
a study by Brown et al30 reported increased responses to a 
human papilloma virus (HPV) vaccine among individuals 
with malaria parasitaemia. In a 2010 review, Cunnington 
and Riley showed that, despite long- standing interest, 
the impact of malaria on vaccine responses was not 
adequately understood.16 Although there is little evidence 
that malaria impairs responses to protein vaccines given 
in multiple doses,16 30 31 they found consistent evidence 
of an adverse effect on the response to polysaccharide 
vaccines.16
Malaria may impact vaccine responses due to acute 
immunological changes (associated with fever),32 or by 
longer term effects (for example on T follicular helper 
cell and B cell function).33 The extent to which infection 
with malaria impacts immunological characteristics asso-
ciated with vaccine responses may best be determined by 
intervention studies. This trial protocol B of the ‘POPVAC’ 
programme has been designed to evaluate the effect of 
IPT of malaria on vaccine responses. We summarise the 
protocol here. This study is one of three parallel trials 
whose designs and cross- cutting analyses are described 
separately in this issue. Understanding the predictors of 
vaccine responses, and the factors that drive them, will 
contribute to finding ways of improving vaccine efficacy 
for rural, tropical settings.
HYPOTHESIS
The overarching goal of the POPVAC programme is to 
understand population differences in vaccine responses 
in Uganda, in order to identify strategies through which 
vaccine effectiveness can be optimised for the low- income, 
tropical settings where they are especially needed. For this 
Trial B, we focus on the hypothesis that malaria infection 
suppresses responses to unrelated vaccines, and that this 
effect can be reversed, at least in part, by IPT of malaria 
in schools in high transmission settings.
OBJECTIVE
To determine whether there are reversible effects of 
malaria infection on vaccine response in adolescents, 
using an intervention study.
METHODS AND ANALYSIS
Design, setting and participants
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) reporting guidelines34 are 
used. We will conduct an individually randomised, 
double- blind, placebo- controlled, parallel group trial of 
 on F









pen: first published as 10.1136/bm





3Natukunda A, et al. BMJ Open 2021;11:e040427. doi:10.1136/bmjopen-2020-040427
Open access
monthly dihydroartemisinin/piperaquine (DP) versus 
placebo among primary school children in rural schools 
in Jinja district, Uganda. We will recruit 640 participants, 
randomising 320 to each trial arm. The study cohort will 
recruit participants aged 9 to 17 years from primary school 
year 1 up to 6 (to avoid primary leaving examinations in 
late year 7, and loss to follow- up of children who leave 
from primary 7). Schools will be selected purposefully to 
assure malaria prevalence appropriate to our design. The 
study setting is remote from Lake Victoria and the River 
Nile, in order to minimise exposure to schistosomiasis.
Recruitment criteria
Inclusion criteria
i. Attending the selected school and planning to con-
tinue to attend the school for the duration of the 
study.
ii. Aged 9 to 17 years and enrolled in primary 1 to 6.
iii. Written informed assent by participant and consent 
by parent or guardian.
iv. Agree to avoid pregnancy for the duration of the trial 
(female only).
v. Willing to provide locator information and to be con-
tacted during the course of the trial.
vi. Able and willing (in the investigator’s opinion) to 
comply with all the study requirements.
Exclusion criteria
i. Clinically significant history of immunodeficiency 
(including HIV), cancer, cardiovascular disease, gas-
trointestinal disease, liver disease, renal disease, en-
docrine disorder or neurological illness.
ii. Moderate or severe acute illness characterised by any 
of the following symptoms: fever, impaired conscious-
ness, convulsions, difficulty in breathing or vomiting; 
or as determined by the attending project clinician.
iii. Family history of sudden death attributable to heart 
condition in a first- degree relative.
iv. Family history of long QT syndrome.
v. Know congenital prolongation of the corrected QT 
(QTc) interval.
vi. History of known heart disease or fainting.
vii. Known allergy or history of adverse reaction to DP or 
to artemether- lumefantrine.
viii. History of serious psychiatric condition or disorder.
ix. Previous immunisation with yellow fever (YF), oral 
typhoid or HPV vaccine; previous immunisation with 
BCG or tetanus and diphtheria vaccine (Td) at age 
>5 years.
x. Concurrent oral or systemic steroid medication or 
the concurrent use of other immunosuppressive 
agents within 2 months prior to enrolment.
xi. Current use of medications known to prolong the QT 
interval.
xii. History of allergic reaction to immunisation or any 
allergy likely to be exacerbated by any component of 
the study vaccines including egg or chicken proteins.
xiii. Tendency to develop keloid scars.
xiv. Haemoglobin less than 80 g/L.
xv. Positive HIV serology.
xvi. Positive pregnancy test.
xvii. Female currently lactating, confirmed pregnancy or 
intention to become pregnant during the trial period.
xviii. Use of an investigational medicinal product or 
non- registered drug, live vaccine, or medical device 
other than the study vaccines for 30 days prior to dos-
ing with the study vaccine, or planned use during the 
study period.
xix. Administration of immunoglobulins and/or any 
blood products within the 3 months preceding the 
planned trial immunisation date.
Further information on recruitment criteria can be 
found in online supplemental information.
Interventions
We will individually randomise participants in a 1:1 ratio 
to an experimental intervention of monthly DP versus 
a DP- matching placebo in a double- blind, placebo- 
controlled trial (figure 1 and online spplemental table 
S1). DP has been shown to reduce prevalence of asymp-
tomatic malaria by 94% and malaria incidence by 96% 
among Ugandan school children.35 The DP treatment 
arm will receive two doses, 1 month apart, prior to the first 
immunisation, followed by monthly treatment thereafter. 
Each dose will be calculated based on the participant’s 
weight (in kg).36 DP (dihydroartemisinin 40 mg+piper-
aquine phosphate 320 mg) tablets will be administered 
once a day for 3 consecutive days. The standard arm will 
receive placebo since, as yet, routine preventive malaria 
treatment in schools is not a Uganda Ministry of Health 
policy.
Randomisation and allocation to treatment arm
An independent statistician will generate the rando-
misation code using a randomly permuted block size. 
This code will be embedded into a web- based rando-
misation system in REDCap (Research Electronic Data 
Capture) software.37 38 At enrolment, eligibility criteria 
will be checked and eligible participants will be allocated 
sequentially to the next randomisation number, with the 
corresponding trial arm designated in REDCap. The 
Figure 1 Outline of immunisations and interventions. 1PE 
will be at 8 weeks post BCG and 4 weeks post yellow fever 
(YF- 17D), oral typhoid (Ty21a), human papilloma virus and 
tetanus/diptheria (Td) vaccination. 2PE for responses to Td 
given at 28 weeks.
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randomisation code will be kept securely by the trial stat-
istician with a second copy held by a data manager or stat-
istician not otherwise involved in the trial at the Medical 
Research Council (MRC)/Uganda Virus Research Insti-
tute (UVRI) and London School of Hygiene and Tropical 
Medicine (LSHTM) Uganda Research Unit.
Blinding
The trial will be double- blind, and will remain so until 
data collection and data cleaning are complete and data 
locked for analysis, unless unblinding is required for indi-
vidual participants who become pregnant (for these cases 
unblinding can be requested by the Principal Investi-
gator) or as a result of serious adverse events or reactions 
(at the request of the Data and Safety Monitoring Board).
Immunisations
We will study a portfolio of licensed vaccines (live and inert, 
oral and parental, priming and boosting) expected to be 
beneficial (in some cases, already given) to adolescents in 
Uganda. Our schedule (table 1 and online supplemental 
table S1) will comprise three main immunisation days (week 
0, week 4 and week 28). Additional HPV immunisation will 
be provided for girls aged 14 years or above, and a second 
Td boost will be given after completion of the study, to 
accord with the national Expanded Programme on Immu-
nisation (EPI) routines but the response to these will not 
specifically be addressed. Further rationale for the selection 
of vaccines is detailed in online supplemental information. 
Our schedule has been developed in consultation with the 
EPI programme and is cognisant of potential interference 
between vaccines (online supplemental information).
Schedule of immunisation and sampling
The schedule of immunisation and sampling is outlined in 
figure 1 and online supplemental table S1. While optimal 
timings for outcome measures vary between vaccines, 
sampling at 8 weeks post BCG and 4 weeks post YF- 17D, 
Ty21a, HPV and Td is proposed for the primary endpoints, 
targeting the establishment of memory responses and 
approximate peak of antibody responses.39–43 A secondary 
endpoint at 1 year will assess waning. All analyses will take 
baseline measurements into account. Immunisation post-




These will be assessed in all participants.
i. BCG: BCG- specific interferon-γ ELISpot response 
8 weeks post BCG immunisation.
ii. YF- 17D: neutralising antibody titres (plaque- reduction 
neutralisation test) at 4 weeks post YF immunisation.
iii. Ty21a: Salmonella typhi lipopolysaccharide- specific IgG 
concentration at 4 weeks post Ty21a immunisation.
iv. HPV: IgG specific for L1- proteins of HPV-16/18 at 
4 weeks post HPV priming immunisation.
v. Td: Td- specific IgG concentration at 4 weeks post Td 
immunisation.
Secondary outcomes
These will be assessed in all participants and will further 
investigate estimates of protective immunity (for vaccines 
where these are available) and dynamics of the vaccine 
responses, as well as the impact of the interventions on para-
site clearance.
Protective immunity
Proportions with protective neutralising antibody 
(YF); protective IgG levels (TT);44 seroconversion 
rates (Ty21a) at 4 weeks post the corresponding 
immunisation.
Response waning
Primary outcome measures (all vaccines) repeated at 
week 52, and area under the curve analyses.
Priming versus boosting
Effects on priming versus boosting will be examined for 
HPV only, comparing outcomes 4 weeks after the first, 
and 4 weeks after the second vaccine dose.




week 4 Immunisation week 8
Immunisation 
week 28 Immunisation week 52







      





*Prior BCG status may vary (data on history and documentation of prior BCG, and presence of a BCG scar, will be documented although 
these approaches have limitations for determining BCG status)
†Both girls and boys will receive the HPV vaccine
‡The National EPI programme recommends three doses of HPV vaccine for older girls
§These doses will be given to comply with guidelines but outcomes specifically relating to these doses will not be assessed.
¶Priming by immunisation in infancy is assumed.
EPI, Expanded Programme on Immunisation; HPV, human papilloma virus; Td, Tetanus/diphtheria.
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Current malaria infection status and intensity
Will be assessed retrospectively by PCR on stored samples 
collected on immunisation days and at week 52.
Furthermore, our sample collection will offer oppor-
tunities for an array of exploratory immunological eval-
uations on stored samples, focussing mainly on vaccine 
antigen- specific outcomes. Exploratory assessments will 
provide further detail on immune response characteris-
tics over the study time- course, and on the role of immu-
nological profiles in malaria- mediated modulation of 
vaccine- specific responses.
Additional evaluation of parasite infection
1. Current Schistosoma mansoni infection status and in-
tensity will be determined by serum/plasma levels 
of circulating anodic antigen (CAA). This method is 
quantitative, highly specific for Schistosoma infection 
and much more sensitive than the conventional Kato 
Katz method.45 CAA will be assessed retrospectively on 
stored samples collected at baseline and at weeks 28 
and 52.
2. Prior exposure to schistosomiasis will be evaluated by 
ELISA for IgG to schistosome egg antigen using stored 
blood samples collected at baseline.
3. The presence of other helminth infections will be de-
termined retrospectively using stool PCR of samples 
collected at baseline and at weeks 28 and 52. In accord 
with national guidelines, all participants will be treated 
with albendazole or mebendazole after collection of 
samples for primary endpoints at week 8 and 28, and 
after collection of samples for secondary endpoints at 
week 52.
4. Malarial fever: Individuals presenting with fever will 
be investigated using rapid diagnostic tests for malaria 
and treated based on the results and according to pre-
vailing national guidelines.
5. Prior malaria exposure will be evaluated by ELISA for 
IgG to malaria antigen using stored samples collected 
at baseline.
Sample size considerations
Based on the literature6 46 47 and preliminary data, we 
anticipate that SD of primary outcome measures will 
lie between 0.3 and 0.6 log10; that responses in rural, 
high- parasite settings may be 0.3 to 0.4 log10 smaller than 
in the urban setting, and that effective treatment of para-
sitic infections may restore responses by approximately 
0.2 log10 (Tweyongyere et al).
48 We therefore power our 
study to detect differences of this magnitude (0.2 log10) 
or (in some cases) smaller. Among 5 to 15 year olds in 
this study setting, previous studies have reported malaria 
prevalence of >50% based on microscopy;21 22 we assume 
malaria prevalence of >60% based on PCR.
Based on these assumptions, we plan to include 640 
participants in total (320 DP and 320 placebo); of whom 
384 are expected to be malaria infected, giving 192 partic-
ipants in each trial arm who are infected at baseline.
Table 2 shows power estimates, for 5% significance level 
and assuming 20% loss to follow- up.
ETHICS AND DISSEMINATION
Ethical approval has been granted from the Research 
Ethics Committees of the UVRI (UVRI REC, reference: 
GC/127/19/05/681) and the LSHTM (reference: 
16033), and from the Uganda National Council for 
Science and Technology (UNCST, reference: HS 2487) 
and the Uganda National Drug Authority (NDA, refer-
ence: CTC0117/2020). Any protocol amendments will be 
submitted to ethics committees and regulatory bodies for 
approval before implementation.
Participants will be adolescents and therefore a vulner-
able human population. Care will be taken to provide 
adequate, age and education- status appropriate informa-
tion and to ensure that it is understood; and to empha-
sise that participation is voluntary. Participants will be 
enrolled only when they have given their own assent and 
when consent has been given by the parent or guardian. 
No major risks to the participants are anticipated since all 
the treatments and vaccines to be given are licensed and 
known to be safe. The main risk to participants will be 
time lost from school work: we will work with teachers and 
parents to minimise disruption to classes, and will avoid 
enrolment of primary seven students since these classes 
are involved in national examinations. Further risks are 
discussed in online supplemental information.




0.08 0.10 0.12 0.14 0.16 0.18 0.20
192 DP vs 192 placebo (malaria infected only)
0.3 65% 83% 94% 98% >99% >99% >99%
0.4 42% 59% 75% 87% 94% 98% 99%
0.5 29% 42% 56% 69% 80% 88% 94%
0.6 21% 31% 42% 53% 65% 75% 83%
Cells highlighted in grey correspond to >80% power.
DP, dihydroartemisinin/piperaquine.
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For this trial, we gave particular consideration to the 
differential provision of malaria treatment. IPT with DP 
is an experimental intervention that has been shown to 
reduce the prevalence of anaemia and reduce episodes 
of clinical malaria in Ugandan schools35 and was shown 
to be safe under suitable exclusion criteria49 but has 
not been adopted as standard of care. To manage the 
expected differential benefits of the interventions for 
anaemia, a full blood count will be performed at baseline, 
as discussed above; anaemic children will be managed 
appropriately and severely anaemic children excluded. 
Additional safety monitoring during the trial will be 
done by the Data and Safety Monitoring Board (DSMB). 
Further information on the DSMB can be found in online 
supplemental information.
Malaria infection status will be determined retrospec-
tively through assays conducted in bulk on stored samples 
(malaria PCR). These results will not, therefore, be 
useful to determine management of individual partici-
pants. Participants in the placebo arms will receive lower 
levels of anti- malaria treatment. However, all trial arms 
will receive a minimum of well- implemented national 
standard of care. Malaria standard of care will comprise 
provision of bed nets to minimise malaria exposure for all 
participants. Rapid diagnostic tests and treatment will be 
made readily available for participants who develop symp-
tomatic malaria.
Study findings will be published through open- access 
peer- reviewed journals, presentations at local, national 
and international conferences and to the local commu-
nity through community meetings. Anonymised partici-
pant level data sets generated will be available on request.
Participant and public involvement
Concepts involved in this work have been discussed with 
colleagues at the Vector Control Division and EPI in 
the Ministry of Health (Uganda). Before commencing 
the trial, discussions will be held with officials at Jinja 
District Council, community leaders and Village Health 
Teams from sub- counties in which selected schools are 
located. In addition, we will engage teachers and parents 
in planning the detailed standard operating procedures 
for the study. Prior to recruitment, we will hold meetings 
to explain the proposed work to teachers, parents and 
students and to address their questions. At the end of the 
study, results will be shared with these stakeholders and 
with participants.
Data management and analysis
Sociodemographic information and clinical and labo-
ratory measurements will be recorded and managed 
using REDCap (Research Electronic Data Capture) 
tools,37 38 with paper- based forms as back- up. All data will 
be recorded under a unique study ID number. When 
paper forms must be used, data will be double entered 
in a study- specific database, with standard checks for 
discrepancies. All data for analysis will be anonymised 
and stored on a secure and password- protected server, 
with access limited to essential research personnel.
The effect of monthly IPT for malaria versus no IPT 
on the outcomes will be analysed using unpaired t- tests, 
with results presented as a mean difference in vaccine 
response measure together with 95% CI and p value. In 
the event of any imbalance in key characteristics between 
trial arms, multivariable regression models will be used 
to adjust for these potential confounders. We anticipate 
that outcomes will be positively skewed, and will apply log 
transformations to normalise distributions before anal-
ysis is conducted. Information on malaria infection status 
will only be available after randomisation. The primary 
analysis will be done on individuals identified as infected 
at baseline (through the randomisation, these will be 
balanced between treatment arms); this will test the 
hypothesis that treating the infection (and subsequent 
reinfections) removes parasite- induced effects on vaccine 
responses. Secondary analyses will include all randomised 
individuals; this will provide insight into the potential 
benefit of the interventions as public health measures.
DISCUSSION
Parasites have long been proposed as modulators of 
vaccine responses;15 16 malaria is highly prevalent in 
settings with poor vaccine responses. Drivers of popula-
tion differences in vaccine response are not fully eluci-
dated; improved understanding is important for effective 
vaccine development and implementation. If treating 
malaria improves vaccine responses, combining parasite 
control with immunisation programmes offers an attrac-
tive, practical public health intervention for schools and 
communities.
This study aims to determine whether treating malaria 
with DP before and after immunisation with unrelated 
vaccines can improve vaccine responses in adolescents. 
The use of DP in this study is considered an attractive 
option for preventive treatment and preventive chemo-
therapy for malaria because of the long half- life of piper-
aquine (approximately 23 days).49 Despite identified 
benefits in reducing episodes of malaria and anaemia,35 
DP has not been adopted as standard of care either in 
Uganda or elsewhere. Although we hypothesise that 
treatment of malaria will improve vaccine responses, it is 
possible that it will negatively impact immune responses, 
or that effects will differ between types of vaccines. This 
study is expected to add further evidence regarding the 
potential benefits of monthly DP for school children by 
determining the effect, whether beneficial or negative, 
on vaccine responses, as well as collecting data on malaria 
infection status, thereby further contributing to policy 
debate in this field.
A concern arises where treatment of malaria with DP 
may have potential adverse effects such as cardiac toxicity, 
particularly dose- dependent prolongation of the QTc 
interval and associated increased risk of arrhythmias. 
There has been concern that provision of multiple doses 
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might increase this risk especially when taken with food. 
However, a recent meta- analysis involving 11 trials of DP 
(9 IPT and 2 treatment trials) involving 14 628 partici-
pants, 3935 of whom received multiple treatments with 
DP, found no evidence to suggest significant cardiac 
toxicity.49 Few of the studies measured electrocardio-
graphic changes, but those that did found no increase in 
QTc intervals with increasing numbers of doses. There-
fore, the use of DP in this study where malaria prevalence 
is high is not expected to pose a significant risk to the 
participants. Also, although the use of DP necessitates 
strict exclusion criteria, based on previous studies in 
Uganda,22 it is not anticipated that many participants will 
meet these exclusion criteria.
We expect about 60% of the adolescents to have malaria 
infection at the outset in the proposed study area. This 
may vary by season and year, and the prevalence could 
be much lower depending on the timing of the start of 
the study. If this becomes the case, the two study arms 
will not be different enough to test our hypothesis. To 
mitigate this, we will work closely with colleagues moni-
toring trends in malaria prevalence in Uganda and adjust 
our study site to optimise the likelihood of achieving the 
expected prevalence.
This interventional study will help us to understand 
how malaria affects responses to commonly used vaccines, 
which will inform implementation of public health 
programmes for immunisation and infection control 
especially in low- income and middle- income countries.
Study timeline
Applications for ethical approval were submitted in May 
2018, with approval received in September 2018 (UVRI 
REC), May 2019 (UNCST), June 2019 (LSHTM) and 
January 2020 (NDA). Collaborator/investigator/trial 
steering committee meetings were also held during 
the initial 12- month planning period. Recruitment to 
POPVAC B is scheduled to commence in February 2021. 
Intervention will be up to 12 months, with completion of 
the project scheduled for April 2022.
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